Why TransEnterix Stock Is Rebounding Today

What happened

TransEnterix (NYSEMKT: TRX), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.

Prior to today's double-digit move, TransEnterix's stock had fallen by more than 40% following the FDA approval of its minimally invasive robotic-surgery system, Senhance, earlier this month, which initially sparked the company's shares to rise by more than 200% in a single day.

So what

The exact cause of this hefty rally, however, isn't altogether clear. TransEnterix's shares appear to be responding to both an unsubstantiated social media rumor of a potential buyout from Johnson & Johnson (NYSE: JNJ) that popped up over the weekend, as well as a new 12-month price target from analysts at Stifel Nicolaus. Specifically, Stifel's analysts hiked their price target from $3.75 to $4.00 this morning, citing a high interest from surgeons in Senhance.

Now what

As I've argued before, TransEnterix would be wise to sell itself at this stage in the game. The company, after all, lacks the financial firepower to launch Senhance on its own, or to compete with the current market-share leader in robotic surgery in a meaningful way.

That said, there's no concrete evidence that J&J -- or any other company for that matter -- is gearing up to make an offer. So, even though a buyout makes sense in a lot of ways, investors probably shouldn't put much stock in this baseless rumor.

All told, TransEnterix is an intriguing stock because of Senhance, but the company still has to figure out how to raise the capital required to back the system's commercial launch. And until that touchstone issue is resolved, I think investors may want to stick to the sidelines with this high-risk, high-reward robotic-surgery play.

10 stocks we like better than Tanzanian Royalty Exploration (US)When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tanzanian Royalty Exploration (US) wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of October 9, 2017

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.